particular, CKD has been recognized as a major cardiovascular risk factor [4] .
Despite the importance of CKD, the number of randomized clinical trials in CKD patients remains small [5] . The heterogeneity of CKD is a major challenge in this respect. While CKD may be relatively stable and benign in some patients, it can be rapidly progressive and associated with many adverse consequences in others. Novel therapeutic strategies are unlikely to be successful unless sub-groups of patients can be identified that are relatively homogenous with respect to the underlying disease, the dominating pathomechanisms and the risk for disease progression and complication development. The reduction in glomerular filtration rate (GFR) and the level of albuminuria and proteinuria are associated with poor prognosis, but otherwise relatively little is yet known about determinants of the course of CKD [3, 6, 7] .
Several studies have shown that CKD patients under the care of nephrologists have a better prognosis than patients not receiving specialized care [8] [9] [10] . This is despite the fact that specific therapies to target CKD are very limited, suggesting that a combination of aspects of nephrological management and complication awareness rather than single interventions are likely to impact on CKD prognosis. The better prognosis of patients cared for by nephrologists suggests that novel therapies need to be validated against the benchmark of existing nephrological care.
However, while much progress has been made in characterizing individuals with CKD in general population cohorts, comparatively little remains known about characteristics of CKD patients under nephrological care. The Chronic Renal Insufficiency Cohort (CRIC) is a large US cohort of 3612 patients with CKD recruited in seven renal centres with a pre-defined composition, aiming for an equal gender distribution and certain proportions of patients with different ethnicities and in different age groups, both in the absence and presence of diabetes mellitus [11, 12] . A similar study is being conducted in Japan [13] . Several other, smaller cohorts with CKD of variable severity have been established in other countries [14] [15] [16] [17] [18] . We have recently enrolled >5200 patients treated by nephrologists into the German Chronic Kidney Disease (GCKD) study, a long-term observational cohort study [19] . Exclusion criteria were deliberately kept unrestrictive and we chose not to predefine cohort composition to reflect the full spectrum of patients under nephrological care. Here we report characteristics of enrolled patients to define the existing risk factors, disease burden and perspectives for improved strategies of care.
M AT E R I A L S A N D M E T H O D S

Study design
The design of the GCKD study has been described previously [19] . To minimize the influence of variability in care and facilitate the detection of novel risk factors and disease modulators beyond aspects of standardized care, the study was designed to investigate only patients under regular care by nephrologists. It was approved by local ethics committees and registered in the national registry for clinical studies (DRKS 00003971).
Inclusion and exclusion criteria
Patients had to be 18-74 years old, and had to fulfil one of the following two criteria: (i) estimated glomerular filtration rate (eGFR) 30-60 mL/min per 1.73 m 2 or (ii) eGFR >60 mL/ min per 1.73 m 2 and 'overt' albuminuria/proteinuria as defined by any of the four following thresholds of urinary albumin or protein excretion: urinary albumin/creatinine >300 mg/g, albuminuria >300 mg/day, urinary protein/creatinine >500 mg/g, or proteinuria >500 mg/day. Screening laboratory values were taken from local laboratories and the GFR defining eligibility was estimated using a locally implemented equation, usually the 4-variable Modification of Diet in Renal Disease (MDRD) formula [20] . Exclusion criteria were solid organ or bone marrow transplantation, active malignancy within 24 months prior to screening, heart failure New York Heart Association Stage IV, legal attendance or inability to provide consent. In addition, patients with non-Caucasian ethnicity were excluded, since they represent a relatively small, heterogeneous group in Germany.
Enrolment
Between March 2010 and March 2012, 5298 patients were enrolled. Eighty-one patients were excluded from final analysis because of invalid informed consent (n = 1), data loss (n = 2) or the presence of exclusion criteria at the time of enrolment (n = 78), resulting in a final cohort of 5217 patients. Of these, 4775 patients (91.5%) were enrolled on the basis of an eGFR between 30 and 60 mL/min per 1.73 m 2 and 442 patients (8.5%) on the basis of an eGFR >60 mL/min per m 2 and overt proteinuria.
Baseline visits
All patients were met by a trained and certified study team in the practice of the nephrologist or in outpatient units of the regional centres. Resting blood pressure was measured thrice in upright position after 3 min sitting time using a standardized device (Omron M5 Professional devices) and the mean is reported. Information was collected on sociodemographic factors, medical and family history, and medications ( prescribed drugs and over the counter drugs). Validated instruments were used to assess health-related quality of life [21] , symptoms of heart failure [22] , angina pectoris [23] and intermittent claudication [24] . Disease, co-morbidity and other parameter definitions were used according to international standards (see Supplementary Table S1 ). Plasma, serum, blood and spot-urine samples were collected, processed and shipped frozen to a central laboratory for routine clinical chemistry of a core set of parameters (Synlab; Heidelberg, Germany), Hb and HbA1C measurements (Central Lab, University Hospital Erlangen, Germany), DNA extraction and storage for future analyses (Central Biobank, University Hospital Erlangen). Laboratory parameters presented throughout this article were all measured using constant methodology. Serum creatinine was analysed using an IDMS traceable methodology (Creatinine plus, Roche). Cystatin C was measured using Tina-quant, Roche. GFR values were calculated using the MDRD IV formula [20] as defined in the study protocol, and creatinine and cystatin C based Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) formulas [25, 26] . Workflows to track sample processing, transportation and storage are quality assured and supported by a dedicated biobank management system [27] . Data collection procedures were monitored by an internal quality control panel that was advised by external reviewers. Patient interviews were recorded and audited for quality control. A two-sided P < 0.05 was considered significant.
Statistical analysis
R E S U LT S
Demographic and clinical characteristics
The mean age at baseline was 60.1 ± 12.0 years. Sixty per cent were male and 35% had diabetes mellitus (39% of men and 29% of women). Baseline demographic and clinical characteristics for male and female patients with and without diabetes are shown in Table 1 . Frequency distributions of age categories according to gender and the absence or presence of diabetes are shown in Supplementary Figure S1 .
The proportion of patients with a positive family history for cardiovascular disease, diabetes and renal disease was large. Among parents, grandparents or siblings, half were reported to have diabetes, three-fourths hypertension and slightly more than one-third stroke or myocardial infarction, respectively. Among this group of relatives 28% had at least one family member with CKD and 7.8% with renal failure; 5.9% requiring dialysis and 1.6% treated with a renal transplant.
Almost 60% of patients in the whole cohort were either current or former smokers, this proportion being lowest in women with diabetes (42%) and highest in men with diabetes (75%).
The mean body mass index (BMI) for the entire cohort was 29.8 kg/m 2 ranging from a mean value of 28.1 kg/m 2 in women without diabetes to 33.4 kg/m 2 in women with diabetes. Overall, 43% of enrolled patients had a BMI >30 kg/m 2 . Mean blood pressure was 139.5/79.3 mmHg. In only slightly more than one quarter it was <130/80 and in only approximately half <140/90 mmHg. Mean blood pressure was 5.5 mmHg higher in men than in women (P < 0.001) and 4.0 mmHg higher in patients with diabetes than in patients without (P < 0.001). Patients reported frequent use of antihypertensive agents. Inhibitors of the renin angiotensin system were most frequently used, with 88% on angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB), 46% on ACE-I only, 35% on ARB only and 7% on a combination of ACE-I and ARB. ACE-I and ARB use was more frequent in men, but there was no consistent difference between patients with and without diabetes. Direct renin inhibitors were used by 5% of the patients. Approximately half of all patients were on diuretics. Diuretics, beta blockers and calcium channel blockers were more frequently used in patients with diabetes.
The mean serum creatinine was 1.5 ± 0.5 mg/dL, corresponding to an eGFR of 47 mL/min per 1.73 m 2 (MDRD) [20] or 49 mL/min per 1.73 m 2 (CKD-EPI creatinine) [25] . In men and women, eGFR was slightly lower if diabetes was present. The distribution of patients in different GFR categories based on GFR estimates using different creatinine and cystatin C based formulas is given in Supplementary Table S2 . The median urinary albumin to creatinine ratio (UACR) was 51 mg/g (Table 1 ). Approximately 30% had a UACR between 30 and 300 or above 300 mg/g, respectively. Median UACR was approximately twice as high in men when compared with women, but similar in patients with and without diabetes.
The distribution of enrolled patients in GFR (MDRD) and albuminuria categories is illustrated in Figure 1 . Based on recently established risk ranking for adverse outcomes according to the levels of eGFR and albuminuria [3, 28] , 24, 33, 33 and 4% of the entire cohort had mildly, moderately, severely and very severely elevated risk, respectively. Measured baseline values for eGFR and UACR of some patients were outside the inclusion range. This could either reflect variability in parameters between enrolment and baseline visit or be due to the fact that enrolment was based on local lab values, whereas baseline parameters were analysed centrally in a highly standardized way. Table 2 summarizes selected demographic and clinical baseline parameters according to the two enrolment strata. The average age of those with overt proteinuria was 15 years lower, while the gender distribution was similar. Rates of positive family history for diabetes, cardiovascular disease and renal disease were also similar between both groups, as was the smoking burden.
Baseline characteristics by inclusion criteria
Causes of renal disease
The three most frequently named leading causes of renal disease were vascular nephropathy (23%), primary glomerulopathy (19%) and diabetic nephropathy (15%), while the leading cause was considered unknown in almost 20% ( Figure 2 and Table 3 ). The renal biopsy rate in the entire cohort was 26%. It varied substantially between patients with (12.6%) and without diabetes (33.6%) ( Table 1) , patients in the two enrolment strata (22.9% versus 61.5%) ( Table 2) , and depending on aetiology (Table 3) .
In patients in whom a leading cause of kidney disease was specified, additional causes were frequently assumed to contribute (Table 3) . The percentage of patients with at least one additional cause ranged from 16% in patients with hereditary a All values are mean and SD with the exception of values for urinary albumin/creatinine ratio, which are presented as median and interquartile range. The number of missing values was <2% for all parameters, except for family history (6-12%). In 6.2% of study participants no data were availbale on medication, which includes patients without any prescriptions.
disease as the leading cause to 49% in patients with acute kidney injury as the leading cause. In patients with unknown leading cause, causes contributing to CKD were specified in almost 70%. In only 41% of patients with diabetes, diabetic nephropathy was considered to be the leading cause of kidney disease; while conversely, 24% of those with leading causes of CKD other than diabetic nephropathy had diabetes. Therefore, baseline characteristics in patients with diabetes were analysed separately for patients with and without presumed diabetic nephropathy in comparison to patients without diabetes (Supplementary  Table S3 ). Demographic, anthropometric, clinical and medication data were very similar in patients with diabetes and CKD with and without presumed diabetic nephropathy, with the exception of a higher UACR in those with presumed diabetic nephropathy.
F I G U R E 1 : Percentage of GCKD study participants in different GFR and albuminuria categories. Colour coding reflects different degrees of increasing risk for all-cause mortality and other adverse outcomes as identified by the CKD prognosis consortium [3, 6, 28] (yellow, mildly; dark yellow, moderately; orange, severely; red, very severely). GFR was estimated using the MDRD formula. Overt albuminuria/proteinuria was defined by any of the four following thresholds of urinary albumin or protein excretion: urinary albumin/creatinine >300 mg/g, albuminuria >300 mg/day, urinary protein/creatinine >500 mg/g, or proteinuria >500 mg/day. The number of missing values was <2% for all parameters, except for family history (6-12%).
Patient knowledge about kidney disease and treatment by nephrologist Figure 3 illustrates how long the presence of kidney disease was known to the patient (from patient questionnaire) and how long patients were treated by a nephrologist (from treating nephrologist questionnaire). Approximately 80% of the patients were under nephrological care for >1 year and >50% for at least 3 years. The time distribution of kidney disease awareness was similar.
Cardiovascular disease burden
The burden of cardiovascular disease at the study onset is substantial. Apart from the presence of arterial hypertension in >95% of patients enrolled, 32% reported at least one of the events specified in Table 4 , or had cardiac valve replacement or aortic aneurysm surgery. In patients with diabetes, the number of events in most event categories was at least approximately 2-fold higher. The cardiovascular disease burden was lower in those patients enrolled with overt proteinuria and eGFR >60 mL/min per 1.73 m 2 when compared with patients with eGFR ≤60 mL/min per 1.73 m 2 ( Table 2) .
D I S C U S S I O N
The analysis of patient characteristics in this large CKD cohort, where approximately 80% of patients have been under nephrological care for at least 1 year, illustrates important challenges for improving the outcome of patients with CKD.
In particular, we observed a remarkable uncertainty about the underlying causes of CKD, a high prevalence of comorbidities and insufficient blood pressure control in many patients. In many patients enrolled, the treating nephrologist assumed a multifactorial aetiology of kidney disease; in almost 20% the leading cause was unknown. Twenty-six per cent of the entire GCKD cohort had undergone a renal biopsy. Renal biopsies were largely confined to patients in whom either primary glomerulopathy or renal involvement in systemic diseases was considered as the most probable cause of CKD. Only 17% in all other disease categories had been biopsied, indicating that diagnostic assessment was mostly made on clinical, biochemical and imaging grounds. Apart from primary glomerulopathy, the two other most frequent categories of leading causes of CKD were diabetic and vascular nephropathy, which are considered as leading causes of CKD worldwide [1, 2] . However, in the absence of specific diagnostic tests and given the low biopsy rate, the diagnostic certainty for both entities may be low. Interestingly, in less than half of the patients with diabetes, diabetic nephropathy was considered to be the leading cause of CKD. Patients who were categorized as having diabetic nephropathy had higher levels of albuminuria than those with diabetes that were not considered to have diabetic nephropathy, presumably reflecting the traditional view that proteinuria is a hallmark of diabetic nephropathy. On the other hand, more than one-third had an UACR below 30 mg/g, which is consistent with studies showing that a relevant proportion of patients with diabetic nephropathy has low levels of albuminuria [29, 30] . Obviously, diabetes is an important F I G U R E 2 : Presumed causes of CKD and the percentage of patients with diabetes and hypertension in whom a specific diagnostic entity was considered as the leading cause. Bars show number of patients in whom a disease entity is considered as the leading cause (light grey) or as either leading or additional cause (dark grey).
contributor to the disease burden in CKD patients far beyond those with presumed diabetic nephropathy. The diabetes prevalence of 35% in GCKD is more than twice as high as in Epidemiologische Studie zu Chancen der Verhütung, Früher-kennung und optimierten THerapie chronischer ERkrankungen in der älteren Bevölkerung (ESTHER) [31] , a general population-based health examination in Germany with similar age distribution (50-74 years; mean age 62.1 years) and almost 4-fold higher than in Study of Health in Pomerania, a general population-based study in northern Germany [32] . It is only slightly higher, however, than the 32% prevalence in individuals with CKD in the US National Health and Nutritional Examination Survey (NHANES) [33] , suggesting that the proportion of diabetics in CKD populations with and without nephrological care in Europe and the USA is similar. Analogous considerations as for patients with diabetes hold true for the large group of patients considered to have vascular nephropathy. The high frequency of arterial hypertension in all diagnostic categories illustrates a lack of discriminative potency. Together with the low biopsy rate in patients with the presumed diagnosis of vascular nephropathy (8%), this suggests a diagnosis on the basis of clinical exclusion of other causes in most cases. The apparent uncertainty in diagnosis and the multifactorial nature of CKD likely reflect important hurdles for testing and implementing novel treatment strategies that target specific pathomechanisms.
Although the GCKD study was not designed to identify risk factors for CKD, several characteristics of the patients enrolled provide indirect evidence for predisposing factors in addition to diabetes and arterial hypertension. First, we observed a gender imbalance, with 60% male study participants. This is consistent with male predominance in patients on dialysis [34] but stands in contrast with studies assessing CKD prevalence in the general population, where the proportion of females is usually larger [31, 33, [35] [36] [37] [38] . The reasons for this difference could include a lower detection rate, as well as gender inequity in referral practice or recruitment bias. Male gender is associated with a higher prevalence of cardiovascular disease (CVD), which might indirectly cause an increased association with CKD. However, the proportion of male patients among those enrolled with overt proteinuria and no significant reduction in GFR, in whom primary renal disease was frequent, was also ∼60%. Secondly, we observed a significant degree of obesity in both men and women. Even in patients without diabetes, approximately one-third had a BMI above 30 kg/m 2 . Although the study recruited across different regions within Germany, there was no centre effect on BMI. Moreover, BMI values observed in the GCKD study are consistent with those in recently reported CKD registry data [39] , but higher than in the general population [32, 37, 38, 40] . This corroborates evidence that obesity may affect kidney function beyond its effect on glucose metabolism and systemic atherosclerosis [41, 42] . Third, almost 60% of the GCKD study participants are current or former smokers, compared with <50% in a population-based study with similar age distribution in Germany [32] . The percentage of smokers was even higher in the subgroup of patients enrolled with proteinuria and eGFR >60 mL/min per m 2 , which had a much smaller proportion of patients with diabetes and cardiovascular disease manifestation. Treating nephrologists were requested to identify the presumed leading cause and additional contributing causes of kidney disease on a CRF form with tic boxes with pre-defined disease categories. Numbers of patients with specific causes of kidney diseases and their proportion are given in the first two columns. Numbers of patients in whom additional contributing causes were specified are presented for each category of leading cause in columns 3-14. Column 15 gives the total number of patients in whom a specific disease entity was considered as either the leading or a contributing cause. Renal biopsy rates are presented in column 16.
These observations are consistent with other data suggesting adverse effects of smoking on kidney function independent of atherosclerosis [43] . Fourth, family history provided evidence for familial aggregation of CKD. Approximately 30% of patients reported that at least one of their parents, grandparents or siblings had CKD and 7.5% were either on dialysis or had a renal transplant. Studies in dialysis patients also found evidence for familial aggregation of renal failure [44, 45] . Apart from adult polycystic kidney disease, monogenic kidney diseases are so far considered to be rare, but evidence for polygenic predisposition for CKD is emerging [46, 47] . Blood pressure control is considered a mainstay of CKD management. Although optimal blood pressure targets in CKD patients remain controversial [48, 49] , the most recent guidelines propose maintaining blood pressure ≤140/90 mmHg in CKD patients with UACR below 30 mg/g and ≤130/80 mmHg in patients with UACR above 30 mg/g [3, 48] . Given that only slightly more than 50% of patients in GCKD had an office blood pressure below 140/90 mmHg and only slightly more than a quarter below 130/80 mmHg, it is obvious that there is a large gap between targets and clinical reality. This is consistent with other CKD cohort studies [12, 13, [15] [16] [17] [18] and suggests a potential for improvement, but also illustrates the difficulties of blood pressure control in CKD. On the other hand, in ESTHER systolic blood pressure was similar and the percentage of individuals with blood pressure below 130/80 mmHg was much smaller, i.e. <12% [50] , reflecting the effect of widespread use of anti-hypertensive medication in GCKD.
F I G U R E 3 : Patient awareness about kidney disease and treatment period by nephrologist. Bars indicate number of patients in each time category: light grey-patient awareness of disease, dark grey-treatment by nephrologist. Data were collected using pre-defined time ranges in questionnaires submitted to the patient (for awareness) and the treating nephrologist (for duration of specialist care). According to the information provided by the nephrologist, more than half of the patients were under nephrological care for at least 3 years. Table 4 . Cardiovascular disease burden in patients enrolled into the GCKD study, stratified by gender and presence and absence of diabetes mellitus (n = 5217) n or mean SD or % n or mean SD or % n or mean SD or % n or mean SD or % n or mean SD or % Protocol and procedures for the GCKD study are similar to those used by the CRIC study [11, 12] , but there are important differences between these two large studies in Europe and the USA. They include the multi-ethnic composition of CRIC with only 45% Caucasians when compared with 100% in the GCKD cohort. Since African Americans show a faster progression to end-stage renal disease than Caucasians [37] , this difference in cohort composition is likely to translate into a lower progression risk in the GCKD study. Additional differences between CRIC and GCKD include the enrolment strata in the CRIC study, through which age-, diabetes-and gender-proportions were pre-defined, as well as differences in health care settings, diet and life-style. The Chronic Kidney Disease Japan Cohort (CKD-JAC) study has exclusively enrolled Japanese patients who have a lower CVD prevalence [13] . Other CKD cohort studies that reported baseline data for comparison are of smaller sample size, such as the Mild and Moderate Kidney Disease study (MMKD; n = 227) [14] , the Chronic Renal Impairment in Birmingham study (CRIB; n = 382) [15] , the Chronic Renal Insufficiency Standards Implementation Study (CRISIS; n = 1325) [16] , the Spanish Morbimortalidad en Enfermedad Renal En pacientNtes diAbéticos y non diabéticos study (MERENA; N = 1129) [17] , and the Canadian study of PRediction of Death, Dialysis and Interim Cardiovascular evenTs (CanPREDDICT; n = 2402) [18] . With the exception of MMKD, all these studies have enrolled patients with more advanced CKD, as reflected by a mean eGFR at enrolment between 22 and 31 mL/min per 1.73 m 2 when compared with 47 mL/min per 1.73 m 2 in GCKD. As an additional difference, the proportion of patients with diabetes in many of these studies is higher than in GCKD (CRIC: 47% [12] , MERENA: 41% [17] , CKD-JAC: 37·6% [13] , CanPREDDICT: 48% [18] ). Due to these differences and its unique composition, the GCKD study complements existing cohorts and will enable international comparisons at multiple levels.
Limitations of the study include a possible recruitment bias at the level of participating centres and at the level of patients that might limit the generalizability of our observations. Reliance on patient-reported history and comorbidities without external validation may introduce some misclassification bias. Furthermore, according to the inclusion criteria the study does not comprise the whole spectrum of CKD in the population; e.g. patients older than 74 years and those with milder and more severe stages of CKD [3] were excluded. The strengths include the cohort size, representing the largest CKD cohort to date worldwide, the ethnically homogenous composition and uniform access of study participants to health care resources. Furthermore the study does not rely on routine clinical or administrative data, but standardized, quality-controlled procedures were implemented for prospective data collection. The large number of study sites that collaborates in the GCKD study ensures diversity and reduces the impact of local policies. The two enrolment strata enable comparisons between patients with primary renal disease and those in whom CKD is primarily due to diabetes and hypertension.
In summary the characteristics of patients enrolled into this large European CKD cohort demonstrate the heavy burden of comorbidities associated with kidney diseases and reflect an important role of several risk factors for kidney disease development. Our observations suggest that apart from risk factor control, an improved aetiological assessment may be necessary to improve patient outcomes. We are not yet in a position to establish associations between patient characteristics and outcomes, but intend to follow study patients for up to 10 years, combining the assessment of the clinical course with biomaterial analysis, and anticipate that this will provide significant opportunities for improved diagnostic and therapeutic strategies.
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